Yukihiro Yokoyama Selected Research

salicylhydroxamic acid (SHAM)

1/2018	Inhibition of Toll-like receptor 4 ameliorates experimental postischemic injury in the cholestatic liver through inhibition of high-mobility group box protein b1 (HMGB1) signaling.
1/2007	Is there any effect of renal failure on the hepatic regeneration capacity following partial hepatectomy in rats?
10/2006	Hepatic arterial flow becomes the primary supply of sinusoids following partial portal vein ligation in rats.
9/2004	Estradiol's effect on portal response to endothelin-1 after trauma-hemorrhage.
12/2003	Upregulation of hepatic prolactin receptor gene expression by 17beta-estradiol following trauma-hemorrhage.
12/2003	Role of thromboxane in producing portal hypertension following trauma-hemorrhage.
1/2003	Mechanism of the salutary effects of 17beta-estradiol following trauma-hemorrhage: direct downregulation of Kupffer cell proinflammatory cytokine production.
12/2002	Endothelin-1 and heme oxygenase-1 as modulators of sinusoidal tone in the stress-exposed rat liver.
5/2002	Endothelin 1 impairs oxygen delivery in livers from LPS-primed animals.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yukihiro Yokoyama Research Topics

Disease

53	Neoplasms (Cancer) 07/2022 - 08/2005
22	Klatskin Tumor 01/2022 - 01/2007
16	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 06/2008
16	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2007
16	Hemorrhage 11/2017 - 01/2002
15	Wounds and Injuries (Trauma) 07/2014 - 01/2002
13	Cholangiocarcinoma 06/2019 - 10/2007
11	Liver Failure 01/2021 - 01/2007
9	Ischemia 01/2018 - 12/2002
9	Hemorrhagic Shock 07/2008 - 07/2003
8	Pancreatic Fistula (Pancreatic Fistulas) 12/2019 - 01/2009
7	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 05/2010
6	Cholangitis 06/2020 - 03/2010
6	Carcinoma (Carcinomatosis) 06/2015 - 01/2007
5	Adenocarcinoma 01/2022 - 01/2012
5	Lymphatic Metastasis 09/2017 - 01/2007
5	Endotoxemia 02/2014 - 05/2002
4	Rectal Neoplasms (Rectal Cancer) 06/2022 - 05/2010
4	Carcinogenesis 12/2021 - 01/2013
4	Carcinoma in Situ 12/2021 - 09/2009
4	Pathologic Constriction (Stenosis) 11/2019 - 05/2014
4	Cholecystitis 07/2018 - 02/2013
4	Inflammation (Inflammations) 01/2018 - 06/2004
4	Breast Neoplasms (Breast Cancer) 09/2016 - 01/2009
3	Esophageal Neoplasms (Esophageal Cancer) 11/2022 - 04/2021
3	Hepatocellular Carcinoma (Hepatoma) 12/2021 - 12/2017
3	Bacteremia 12/2021 - 03/2014
3	Infections 01/2021 - 04/2011
3	Gallbladder Neoplasms (Gallbladder Cancer) 11/2019 - 01/2012
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2018 - 10/2012
3	Portal Hypertension 10/2006 - 03/2003
2	Margins of Excision 06/2022 - 12/2014
2	Liposarcoma 02/2022 - 05/2020
2	Obstructive Jaundice (Cholestatic Jaundice) 01/2022 - 11/2017
2	Surgical Wound Infection 01/2021 - 01/2018
2	Malnutrition (Nutritional Deficiencies) 11/2020 - 01/2007
2	Diabetes Mellitus 11/2020 - 01/2007
2	Hyperbilirubinemia 12/2018 - 05/2011
2	Necrosis 01/2018 - 10/2006
2	Hypertrophy 12/2017 - 04/2015
2	Cysts 12/2017 - 06/2015

Drug/Important Bio-Agent (IBA)

9	salicylhydroxamic acid (SHAM)IBA 01/2018 - 05/2002
8	BilirubinIBA 10/2019 - 05/2011
7	Small Interfering RNA (siRNA)IBA 01/2018 - 10/2007
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2010
5	Gemcitabine FDA Link 01/2022 - 02/2017
5	Proteins (Proteins, Gene)FDA Link 05/2019 - 01/2012
4	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 01/2008
4	Indocyanine Green (Cardio-Green)FDA LinkGeneric 06/2016 - 07/2003
4	Ringer's LactateIBA 07/2008 - 06/2004
4	Lactic Acid (Lactate)FDA LinkGeneric 12/2004 - 07/2003
4	Interleukin-6 (Interleukin 6)IBA 12/2004 - 01/2003
3	Anti-Bacterial Agents (Antibiotics)IBA 11/2022 - 04/2011
3	BismuthIBA 07/2022 - 07/2010
3	folfirinoxIBA 01/2022 - 10/2015
3	130-nm albumin-bound paclitaxelIBA 01/2022 - 01/2018
3	AlbuminsIBA 12/2021 - 06/2004
3	MucinsIBA 10/2021 - 05/2015
3	Fluorouracil (Carac)FDA LinkGeneric 11/2020 - 05/2016
3	Trefoil FactorsIBA 01/2020 - 09/2017
3	Biological ProductsIBA 12/2017 - 05/2014
3	Pharmaceutical PreparationsIBA 01/2017 - 01/2013
3	bisabolol (levomenol)IBA 01/2017 - 12/2011
3	Ethanol (Ethyl Alcohol)IBA 06/2015 - 01/2007
3	Cisplatin (Platino)FDA LinkGeneric 04/2013 - 05/2010
3	CytokinesIBA 07/2008 - 01/2003
3	ThromboxanesIBA 08/2005 - 03/2003
3	SolutionsIBA 09/2004 - 07/2003
3	Estradiol (Delestrogen)FDA LinkGeneric 09/2004 - 01/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2004 - 01/2003
2	Oxygen (Dioxygen)IBA 11/2022 - 05/2002
2	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2022 - 05/2020
2	Ifosfamide FDA LinkGeneric 02/2022 - 05/2020
2	Trefoil Factor-1IBA 01/2022 - 01/2018
2	AntigensIBA 01/2021 - 10/2010
2	CarbohydratesIBA 01/2021 - 10/2010
2	Irinotecan (Camptosar)FDA LinkGeneric 11/2020 - 10/2015
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2018
2	perfluoro- 2,2,2',2'- tetramethyl- 4,4'- bis(1,3- dioxolane)IBA 11/2019 - 12/2014
2	ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA 01/2018 - 02/2014

Therapy/Procedure

51	Hepatectomy 01/2022 - 08/2005
19	Laparotomy 12/2021 - 01/2003
17	Therapeutics 08/2020 - 06/2008
16	Pancreaticoduodenectomy 01/2021 - 08/2005
14	Drug Therapy (Chemotherapy) 02/2022 - 07/2012
12	Resuscitation 07/2008 - 01/2003
8	Length of Stay 11/2022 - 01/2007
6	Neoadjuvant Therapy 01/2022 - 05/2010
5	Laparoscopic Cholecystectomy 07/2018 - 02/2013
5	Ligation 01/2018 - 04/2002
4	Esophagectomy 11/2022 - 03/2014
4	Adjuvant Chemotherapy 02/2022 - 04/2013
4	Stents 10/2015 - 05/2013
3	Pelvic Exenteration 06/2022 - 01/2012
3	Operative Surgical Procedures 11/2017 - 12/2014
2	Preoperative Exercise 07/2021 - 01/2019
2	Cholecystectomy 11/2019 - 12/2017
2	Chemoradiotherapy 05/2019 - 01/2018
2	Blood Transfusion (Blood Transfusions) 12/2018 - 02/2016
2	Splenectomy 01/2018 - 01/2009